loading
Axsome Therapeutics Inc stock is traded at $92.17, with a volume of 257.29K. It is down -1.21% in the last 24 hours and down -1.40% over the past month. Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$93.17
Open:
$93.29
24h Volume:
257.29K
Relative Volume:
0.57
Market Cap:
$4.48B
Revenue:
$291.49M
Net Income/Loss:
$-308.55M
P/E Ratio:
-20.35
EPS:
-4.53
Net Cash Flow:
$-168.02M
1W Performance:
+1.17%
1M Performance:
-1.40%
6M Performance:
+20.25%
1Y Performance:
+53.71%
1-Day Range:
Value
$91.78
$95.00
1-Week Range:
Value
$91.78
$105.00
52-Week Range:
Value
$58.61
$105.00

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name
Name
Axsome Therapeutics Inc
Name
Phone
(212) 332-3241
Name
Address
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Name
Employee
569
Name
Twitter
Name
Next Earnings Date
2024-12-12
Name
Latest SEC Filings
Name
AXSM's Discussions on Twitter

Compare AXSM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
AXSM 92.17 4.48B 291.49M -308.55M -168.02M -4.53
VRTX 466.97 119.83B 10.63B -479.80M -1.35B 13.33
REGN 759.96 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 564.96 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 231.31 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.40 24.08B 3.30B -501.07M 1.03B 11.54

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-03-24 Initiated Wells Fargo Overweight
Aug-06-24 Upgrade BofA Securities Neutral → Buy
Jul-22-24 Initiated Needham Buy
Apr-29-24 Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-19-24 Initiated Robert W. Baird Outperform
Feb-06-24 Initiated UBS Buy
Jan-25-24 Initiated RBC Capital Mkts Outperform
Dec-13-23 Initiated Citigroup Buy
Aug-08-23 Upgrade BofA Securities Underperform → Neutral
Jan-05-23 Initiated Piper Sandler Neutral
Nov-01-22 Initiated Loop Capital Buy
Sep-07-22 Resumed Mizuho Buy
Aug-10-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-10-21 Initiated Berenberg Buy
Jan-08-21 Initiated Jefferies Buy
Dec-16-20 Initiated Mizuho Buy
Sep-29-20 Initiated BofA Securities Underperform
Sep-10-20 Initiated Morgan Stanley Overweight
Apr-28-20 Reiterated H.C. Wainwright Buy
Apr-14-20 Initiated Cowen Outperform
Dec-30-19 Reiterated H.C. Wainwright Buy
Dec-17-19 Reiterated H.C. Wainwright Buy
Dec-16-19 Reiterated Guggenheim Buy
Oct-16-19 Initiated Guggenheim Buy
Sep-18-19 Initiated William Blair Outperform
May-28-19 Initiated SunTrust Buy
May-23-19 Reiterated H.C. Wainwright Buy
Apr-08-19 Initiated SVB Leerink Outperform
Mar-15-19 Reiterated H.C. Wainwright Buy
Oct-03-16 Resumed Brean Capital Buy
Dec-15-15 Initiated Cantor Fitzgerald Buy
Dec-14-15 Initiated Ladenburg Thalmann Buy
View All

Axsome Therapeutics Inc Stock (AXSM) Latest News

pulisher
Nov 17, 2024

Is It Too Late to Buy Viking Therapeutics Stock? - The Motley Fool

Nov 17, 2024
pulisher
Nov 15, 2024

FY2024 EPS Estimates for AXSM Increased by Leerink Partnrs - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript - AOL

Nov 14, 2024
pulisher
Nov 14, 2024

Axsome Therapeutics Inc (AXSM) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 14, 2024

Axsome Advances Sleep Disorder Pipeline as Sunosi Prescriptions Increase in Q3 - Sleep Review

Nov 14, 2024
pulisher
Nov 14, 2024

Equities Analysts Offer Predictions for AXSM FY2027 Earnings - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

William Blair Issues Pessimistic Outlook for AXSM Earnings - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Axsome stock price target increased, rating held on strong sales - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Axsome stock price target increased, rating held on strong sales By Investing.com - Investing.com UK

Nov 13, 2024
pulisher
Nov 13, 2024

Axsome Therapeutics stock hits 52-week high at $98.61 By Investing.com - Investing.com Nigeria

Nov 13, 2024
pulisher
Nov 13, 2024

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024
pulisher
Nov 13, 2024

Robert W. Baird Raises Axsome Therapeutics (NASDAQ:AXSM) Price Target to $116.00 - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Earnings call: Axsome Therapeutics reports record quarterly revenue By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 13, 2024

Versor Investments LP Acquires New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Nov 13, 2024
pulisher
Nov 12, 2024

Axsome Therapeutics’ Strong Q3 Growth Amidst Strategic Expansions - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Axsome: Q3 Earnings Snapshot - Houston Chronicle

Nov 12, 2024
pulisher
Nov 12, 2024

Earnings call: Axsome Therapeutics reports record quarterly revenue - Investing.com

Nov 12, 2024
pulisher
Nov 12, 2024

Axsome Therapeutics stock hits 52-week high at $98.61 - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

Axsome shares rise as Guggenheim lifts target to $135 By Investing.com - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

Axsome Therapeutics Q3 Earnings: Stay For Near Term Catalysts, Then Sell (AXSM) - Seeking Alpha

Nov 12, 2024
pulisher
Nov 12, 2024

Axsome Therapeutics (NASDAQ:AXSM) Reaches New 52-Week HighShould You Buy? - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics - Benzinga

Nov 12, 2024
pulisher
Nov 12, 2024

Axsome Therapeutics Inc earnings beat by $0.04, revenue topped estimates - Investing.com

Nov 12, 2024
pulisher
Nov 12, 2024

Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Axsome Therapeutics' (AXSM) Buy Rating Reiterated at Needham & Company LLC - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Axsome (AXSM) Soars: Q3 Revenue Surges 81% to $105M, Auvelity Sales Double | AXSM Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 10, 2024

(AXSM) Proactive Strategies - Stock Traders Daily

Nov 10, 2024
pulisher
Nov 10, 2024

Privium Fund Management B.V. Grows Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Nov 10, 2024
pulisher
Nov 09, 2024

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Position Decreased by Lindbrook Capital LLC - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 - GlobeNewswire

Nov 08, 2024
pulisher
Nov 08, 2024

Axsome Therapeutics to Present Breakthrough CNS Data Across 3 Major Disorders at NEI 2024 | AXSM Stock News - StockTitan

Nov 08, 2024
pulisher
Nov 05, 2024

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Nov 05, 2024
pulisher
Nov 05, 2024

Axsome Therapeutics (AXSM) to Release Earnings on Tuesday - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Position Trimmed by abrdn plc - MarketBeat

Nov 05, 2024
pulisher
Nov 04, 2024

Assenagon Asset Management S.A. Lowers Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Nov 04, 2024
pulisher
Nov 01, 2024

Analysts Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) Target Price at $124.64 - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

(AXSM) Trading Advice - Stock Traders Daily

Oct 31, 2024
pulisher
Oct 30, 2024

Upcoming Opportunities in Hypersomnia Therapeutics Market: - openPR

Oct 30, 2024
pulisher
Oct 29, 2024

Axsome Therapeutics' (NASDAQ:AXSM) investors will be pleased with their impressive 257% return over the last five years - Simply Wall St

Oct 29, 2024
pulisher
Oct 29, 2024

Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail

Oct 29, 2024
pulisher
Oct 29, 2024

Major Depressive Disorder Market Expected to Experience Major - openPR

Oct 29, 2024
pulisher
Oct 29, 2024

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 - The Manila Times

Oct 29, 2024
pulisher
Oct 29, 2024

Axsome Therapeutics Presents Data from Multiple Programs - GlobeNewswire

Oct 29, 2024
pulisher
Oct 25, 2024

Values First Advisors Inc. Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Oct 25, 2024
pulisher
Oct 24, 2024

Hennion & Walsh Asset Management Inc. Has $5.23 Million Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Oct 24, 2024

Axsome Therapeutics Inc Stock (AXSM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Axsome Therapeutics Inc Stock (AXSM) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Saad Mark E
Director
Sep 11 '24
Sale
91.31
11,016
1,005,871
10,002
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$358.51
price down icon 1.26%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):